Evolution and Clinical Translation of Drug Delivery Nanomaterials.

Citation data:

Nano today, ISSN: 1748-0132, Vol: 15, Page: 91-106

Publication Year:
2017
Usage 31
Abstract Views 29
Link-outs 2
Captures 64
Readers 64
Social Media 581
Shares, Likes & Comments 555
Tweets 26
Citations 11
Citation Indexes 11
PMID:
29225665
DOI:
10.1016/j.nantod.2017.06.008
Author(s):
Hassan, Shabir; Prakash, Gyan; Ozturk, Aycabal; Saghazadeh, Saghi; Sohail, Mohammad Farhan; Seo, Jungmok; Dockmeci, Mehmet; Zhang, Yu Shrike; Khademhosseini, Ali
Publisher(s):
Elsevier BV
Tags:
Biochemistry, Genetics and Molecular Biology; Chemical Engineering; Engineering; Materials Science; Pharmacology, Toxicology and Pharmaceutics
Most Recent Tweet View All Tweets
article description
With the advent of technology, the role of nanomaterials in medicine has grown exponentially in the last few decades. The main advantage of such materials has been exploited in drug delivery applications, due to their effective targeting that in turn reduces systemic toxicity compared to the conventional routes of drug administration. Even though these materials offer broad flexibility based on targeting tissue, disease, and drug payload, the demand for more effective yet highly biocompatible nanomaterial-based drugs is increasing. While therapeutically improved and safe materials have been introduced in nanomedicine platforms, issues related to their degradation rates and bio-distribution still exist, thus making their successful translation for human use very challenging. Researchers are constantly improving upon novel nanomaterials that are safer and more effective not only as therapeutic agents but as diagnostic tools as well, making the research in the field of nanomedicine ever more fascinating. In this review stress has been made on the evolution of nanomaterials that have been approved for clinical applications by the United States Food and Drug Administration Agency (FDA).